Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor ... Low white blood cell counts (neutropenia). Low white blood cell counts are very common during treatment with KISQALI and may ...

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

The Food and Drug Administration (FDA) has just approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor as treatment for people with HR+/HER2- stage II and III early breast ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Some treatments that may be used include: Drugs that stimulate the bone marrow: For chemotherapy-induced neutropenia and some other causes, the growth factors Leukine, Neupogen, Neulasta, or Ryzneuta ...